

# ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

13 November 2025

## ECS Botanics completes A\$1.95 million placement to fund international growth and product expansion

### Highlights:

- ECS has received firm commitments to raise A\$1.95 million via a strongly supported Placement to institutional and sophisticated investors
- Funds to be used for international growth initiatives, inventory build and new product registrations
- Participants to receive one free attaching option per share, exercisable at A\$0.011, subject to shareholder approval
- Loyalty Option issue planned for existing shareholders on the same terms as the Placement Options

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to advise it has received binding commitments to raise approximately A\$1.95 million (before costs) through the issue of approximately 300 million new fully paid ordinary shares at A\$0.0065 per share (the "Placement Price").

The Placement was well supported by new and existing institutional and sophisticated investors, reflecting growing market confidence in ECS's strategy and momentum across its B2C and international business units.

Proceeds from the Placement, together with existing cash and debt facilities, will be directed towards:

- Funding new product registrations, including innovative delivery formats for the ECS product range;
- Strategic inventory purchases to support growing domestic and export sales volumes; and
- Expansion of ECS's international distribution footprint, particularly in Europe.

Commenting on the Placement, ECS Managing Director Nan-Maree Schoerie said:

*"This is a pivotal time for ECS as we continue to scale up both our product portfolio and our global distribution strategy. The strong demand for this raise reflects confidence in the business trajectory and positions ECS to accelerate growth across key markets. We are pleased to welcome new investors and appreciate the ongoing support of existing shareholders as we deliver on our vision for ECS as a leading developer of globally relevant medicinal cannabis brands."*



## Placement Terms and Timetable

The Placement Price of A\$0.0065 per New Share represents a discount of 18.8% to the Company's last closing price of A\$0.0080 on 10 November 2025 and 15.6% to the 5-day volume weighted average price of A\$0.0077 on 10 November 2025.

The Placement shares will be issued under ECS's existing placement capacity pursuant to ASX Listing Rules 7.1 and 7.1A. Shares issued under the Placement will rank equally with existing shares and are expected to settle on Wednesday, 19 November 2025, with allotment and trading on the ASX to occur on Thursday, 20 November 2025.

As part of the Placement, participants will also receive one (1) free attaching option for every one (1) New Share issued. These options will be exercisable at A\$0.011 (a ~69% premium to the Placement Price) and will expire 2.5 years from the date of issue. The options will be issued subject to shareholder approval at a forthcoming Extraordinary General Meeting (EGM), which is expected to be held before the end of calendar year 2025. Quotation of these options will also be sought, subject to shareholder approval and ASX requirements.

Additionally, the Company intends to reward shareholder loyalty by issuing Loyalty Options on the same terms as the Placement Options, on a 1-for-6 basis to eligible shareholders on the record date. Further details regarding the Loyalty Option issue and timetable will be released within 45 business days.

Canaccord Genuity (Australia) and GBA Capital acted as Joint Lead Managers to the Placement and will receive a fee equal to 6% of total funds raised, and 10,000,000 options on the same terms as the Placement Options to be split equally (Joint Lead Manager Options). The Joint Lead Manager Options will be subject to shareholder approval at the Company's forthcoming EGM.

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

## Investors and Media

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: [tim@nwrcommunications.com.au](mailto:tim@nwrcommunications.com.au)

## About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.